-
1
-
-
0030758403
-
Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin
-
Poyner DR Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin. Biochem Soc Trans 1997, 25:1032-1036.
-
(1997)
Biochem Soc Trans
, vol.25
, pp. 1032-1036
-
-
Poyner, D.R.1
-
2
-
-
84937517146
-
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
-
Edvinsson L CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. B J Clin Pharmacol 2015, 80:193-199.
-
(2015)
B J Clin Pharmacol
, vol.80
, pp. 193-199
-
-
Edvinsson, L.1
-
3
-
-
78649940547
-
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
-
Eftekhari S, Edvinsson L Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 2010, 3:369-378.
-
(2010)
Ther Adv Neurol Disord
, vol.3
, pp. 369-378
-
-
Eftekhari, S.1
Edvinsson, L.2
-
4
-
-
0035170345
-
Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications
-
Edvinsson L Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 2001, 15:745-753.
-
(2001)
CNS Drugs
, vol.15
, pp. 745-753
-
-
Edvinsson, L.1
-
5
-
-
0025143541
-
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
-
Goadsby PJ, Edvinsson L, Ekman R Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28:183-187.
-
(1990)
Ann Neurol
, vol.28
, pp. 183-187
-
-
Goadsby, P.J.1
Edvinsson, L.2
Ekman, R.3
-
6
-
-
0027509161
-
The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
-
Goadsby PJ, Edvinsson L The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
-
(1993)
Ann Neurol
, vol.33
, pp. 48-56
-
-
Goadsby, P.J.1
Edvinsson, L.2
-
7
-
-
77957922955
-
CGRP and its receptors provide new insights into migraine pathophysiology
-
Ho TW, Edvinsson L, Goadsby PJ CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010, 6:573-582.
-
(2010)
Nat Rev Neurol
, vol.6
, pp. 573-582
-
-
Ho, T.W.1
Edvinsson, L.2
Goadsby, P.J.3
-
8
-
-
30044452563
-
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches
-
Goadsby PJ Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 2005, 65:2557-2567.
-
(2005)
Drugs
, vol.65
, pp. 2557-2567
-
-
Goadsby, P.J.1
-
9
-
-
84857084559
-
Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation
-
Raddant AC, Russo AF Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 2011, 13:e36.
-
(2011)
Expert Rev Mol Med
, vol.13
, pp. e36
-
-
Raddant, A.C.1
Russo, A.F.2
-
10
-
-
57649233374
-
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
-
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008, 372:2115-2123.
-
(2008)
Lancet
, vol.372
, pp. 2115-2123
-
-
Ho, T.W.1
Ferrari, M.D.2
Dodick, D.W.3
-
11
-
-
1542346238
-
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
-
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
-
(2004)
N Engl J Med
, vol.350
, pp. 1104-1110
-
-
Olesen, J.1
Diener, H.C.2
Husstedt, I.W.3
-
12
-
-
79953220801
-
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study
-
Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011, 31:573-584.
-
(2011)
Cephalalgia
, vol.31
, pp. 573-584
-
-
Diener, H.C.1
Barbanti, P.2
Dahlof, C.3
Reuter, U.4
Habeck, J.5
Podhorna, J.6
-
13
-
-
84892162373
-
BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial
-
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014, 34:114-125.
-
(2014)
Cephalalgia
, vol.34
, pp. 114-125
-
-
Marcus, R.1
Goadsby, P.J.2
Dodick, D.3
Stock, D.4
Manos, G.5
Fischer, T.Z.6
-
14
-
-
79954607744
-
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
-
Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011, 31:712-722.
-
(2011)
Cephalalgia
, vol.31
, pp. 712-722
-
-
Hewitt, D.J.1
Aurora, S.K.2
Dodick, D.W.3
-
15
-
-
84907987732
-
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
-
Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014, 83:958-966.
-
(2014)
Neurology
, vol.83
, pp. 958-966
-
-
Ho, T.W.1
Connor, K.M.2
Zhang, Y.3
-
16
-
-
84907964596
-
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
-
Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, 13:1100-1107.
-
(2014)
Lancet Neurol
, vol.13
, pp. 1100-1107
-
-
Dodick, D.W.1
Goadsby, P.J.2
Silberstein, S.D.3
-
17
-
-
84906262129
-
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
-
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
-
(2014)
Lancet Neurol
, vol.13
, pp. 885-892
-
-
Dodick, D.W.1
Goadsby, P.J.2
Spierings, E.L.3
Scherer, J.C.4
Sweeney, S.P.5
Grayzel, D.S.6
-
19
-
-
1442265540
-
The international classification of headache disorders: 2nd edition
-
The international classification of headache disorders: 2nd edition. Cephalalgia 2004, 24(suppl 1):9-160. Headache Classification Subcommittee of the International Headache Society.
-
(2004)
Cephalalgia
, vol.24
, pp. 9-160
-
-
-
20
-
-
54749097210
-
Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment
-
Bigal ME, Serrano D, Reed M, Lipton RB Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008, 71:559-566.
-
(2008)
Neurology
, vol.71
, pp. 559-566
-
-
Bigal, M.E.1
Serrano, D.2
Reed, M.3
Lipton, R.B.4
-
21
-
-
0346106232
-
Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine
-
Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003, 43:336-342.
-
(2003)
Headache
, vol.43
, pp. 336-342
-
-
Bigal, M.E.1
Rapoport, A.M.2
Lipton, R.B.3
Tepper, S.J.4
Sheftell, F.D.5
-
22
-
-
2342480348
-
Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios
-
Harwood RH, Sayer AA, Hirschfeld M Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004, 82:251-258.
-
(2004)
Bull World Health Organ
, vol.82
, pp. 251-258
-
-
Harwood, R.H.1
Sayer, A.A.2
Hirschfeld, M.3
-
23
-
-
75749093649
-
Employment and work impact of chronic migraine and episodic migraine
-
Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 2010, 52:8-14.
-
(2010)
J Occup Environ Med
, vol.52
, pp. 8-14
-
-
Stewart, W.F.1
Wood, G.C.2
Manack, A.3
Varon, S.F.4
Buse, D.C.5
Lipton, R.B.6
-
24
-
-
84881554254
-
Psychiatric comorbidities of episodic and chronic migraine
-
Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB Psychiatric comorbidities of episodic and chronic migraine. J Neurol 2013, 260:1960-1969.
-
(2013)
J Neurol
, vol.260
, pp. 1960-1969
-
-
Buse, D.C.1
Silberstein, S.D.2
Manack, A.N.3
Papapetropoulos, S.4
Lipton, R.B.5
-
25
-
-
77953223552
-
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
-
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30:804-814.
-
(2010)
Cephalalgia
, vol.30
, pp. 804-814
-
-
Diener, H.C.1
Dodick, D.W.2
Aurora, S.K.3
-
26
-
-
77953194100
-
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
-
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30:793-803.
-
(2010)
Cephalalgia
, vol.30
, pp. 793-803
-
-
Aurora, S.K.1
Dodick, D.W.2
Turkel, C.C.3
-
27
-
-
84908158935
-
Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP
-
Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014, 34:968-976.
-
(2014)
Cephalalgia
, vol.34
, pp. 968-976
-
-
Bigal, M.E.1
Walter, S.2
Bronson, M.3
Alibhoy, A.4
Escandon, R.5
-
28
-
-
84903783970
-
Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide
-
Walter S, Alibhoy A, Escandon R, Bigal ME Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. mAbs 2014, 6:871-878.
-
(2014)
mAbs
, vol.6
, pp. 871-878
-
-
Walter, S.1
Alibhoy, A.2
Escandon, R.3
Bigal, M.E.4
-
29
-
-
84944059855
-
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
-
published online Sept 30.
-
Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurology 2015, published online Sept 30. http://dx.doi.org/10.1016/S1474-4422(15)00249-5.
-
(2015)
Lancet Neurology
-
-
Bigal, M.E.1
Dodick, D.W.2
Rapoport, A.M.3
-
30
-
-
84879990242
-
The International Classification of Headache Disorders, 3rd edition (beta version)
-
The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013, 33:629-808. Headache Classification Committee of the International Headache Society (IHS).
-
(2013)
Cephalalgia
, vol.33
, pp. 629-808
-
-
-
31
-
-
84924709870
-
TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine
-
Walter S, Bigal ME TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep 2015, 19:476.
-
(2015)
Curr Pain Headache Rep
, vol.19
, pp. 476
-
-
Walter, S.1
Bigal, M.E.2
-
32
-
-
84876038240
-
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)
-
Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 2013, 53:644-655.
-
(2013)
Headache
, vol.53
, pp. 644-655
-
-
Blumenfeld, A.M.1
Bloudek, L.M.2
Becker, W.J.3
-
33
-
-
56749176453
-
CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
-
Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008, 155:1093-1103.
-
(2008)
Br J Pharmacol
, vol.155
, pp. 1093-1103
-
-
Zeller, J.1
Poulsen, K.T.2
Sutton, J.E.3
-
35
-
-
0029832047
-
Classification of daily and near-daily headaches: field trial of revised IHS criteria
-
Silberstein SD, Lipton RB, Sliwinski M Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871-875.
-
(1996)
Neurology
, vol.47
, pp. 871-875
-
-
Silberstein, S.D.1
Lipton, R.B.2
Sliwinski, M.3
-
36
-
-
84901046526
-
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program
-
Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia 2013, 34:483-492.
-
(2013)
Cephalalgia
, vol.34
, pp. 483-492
-
-
Bigal, M.E.1
Escandon, R.2
Bronson, M.3
-
37
-
-
84944102058
-
-
(accessed April 20, 2015).
-
Guidance for industry: assay development for immunogenicity testing of therapeutic proteins US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Center for Biologics Evaluation and Research (CBER), (accessed April 20, 2015). http://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf.
-
-
-
-
38
-
-
0036657349
-
Chronic daily headache: identification of factors associated with induction and transformation
-
Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42:575-581.
-
(2002)
Headache
, vol.42
, pp. 575-581
-
-
Bigal, M.E.1
Sheftell, F.D.2
Rapoport, A.M.3
Tepper, S.J.4
Lipton, R.B.5
-
39
-
-
79952026321
-
Rates, predictors, and consequences of remission from chronic migraine to episodic migraine
-
Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011, 76:711-718.
-
(2011)
Neurology
, vol.76
, pp. 711-718
-
-
Manack, A.1
Buse, D.C.2
Serrano, D.3
Turkel, C.C.4
Lipton, R.B.5
-
40
-
-
80054734731
-
OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program
-
Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011, 51:1358-1373.
-
(2011)
Headache
, vol.51
, pp. 1358-1373
-
-
Aurora, S.K.1
Winner, P.2
Freeman, M.C.3
-
41
-
-
84888324384
-
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
-
Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013, 81:1191-1196.
-
(2013)
Neurology
, vol.81
, pp. 1191-1196
-
-
Cernuda-Morollon, E.1
Larrosa, D.2
Ramon, C.3
Vega, J.4
Martinez-Camblor, P.5
Pascual, J.6
-
42
-
-
84921485397
-
Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics
-
Stanimirovic DB, Bani-Yaghoub M, Perkins M, Haqqani AS Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics. Expert Opin Drug Discov 2015, 10:141-155.
-
(2015)
Expert Opin Drug Discov
, vol.10
, pp. 141-155
-
-
Stanimirovic, D.B.1
Bani-Yaghoub, M.2
Perkins, M.3
Haqqani, A.S.4
-
43
-
-
84923335592
-
Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier
-
Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 2015, 1600:93-109.
-
(2015)
Brain Res
, vol.1600
, pp. 93-109
-
-
Eftekhari, S.1
Salvatore, C.A.2
Johansson, S.3
Chen, T.B.4
Zeng, Z.5
Edvinsson, L.6
-
44
-
-
17244383233
-
Migraine pathophysiology
-
Goadsby PJ Migraine pathophysiology. Headache 2005, 45(suppl 1):S14-S24.
-
(2005)
Headache
, vol.45
, pp. S14-S24
-
-
Goadsby, P.J.1
|